Akoya Biosciences (NASDAQ:AKYA) Bolsa

AKOYA BIOSCIENCES INC

Akoya Biosciences

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Akoya Biosciences Inc

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 18.77% on an annualized basis producing an average annual return of 37.22%. Currently, Krystal Biotech has a market capitalization of $5.45 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $525.21 today based on a price of $189.18 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742425218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

KRYS

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44258002/wall-street-drop-deepens-as-trade-war-fears-escalate-sp-500-hits-7-month-lows-wha">Stock market turbulence</a> has rattled investors recently, but Kevin O'Leary, also known as &#8220;Mr. Wonderful,&#8221; sees opportunity in the downturn. Despite widespread losses, O'Leary believes now is the time to buy—just don't expect to catch the bottom.
<h2 class="wp-block-heading">Buying During Market Declines</h2>
&#8220;Nobody likes volatility,&#8221; O'Leary acknowledged in a recent <a href="https://www.youtube.com/watch?v=qX1pZvus5Uo">interview</a> with Yahoo Finance. &#8220;But as an investor, you learn that you have to hold your nose. And when there's blood in the streets, you have to be buying.&#8221;
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
O'Leary pointed out that the average company on the Nasdaq has dropped 30% to 40%, while the Russell 2000 index is filled with undervalued stocks. Rather than trying to time the market, he has been buying indices that follow specific rules, including ALPS O&#8217;Shares US Quality Dividend ETF fund (CBOE: OUSA) for the S&amp;P 500 and ALPS O&#8217;Shares US Small-Cap Quality Dividend ETF (CBOE: OUSM) for the Russell 2000.
&#8220;I bought more because it&#8217;s on sale,&#8221; he explained. &#8220;This always happens. Everybody feels, ‘Oh my goodness, it's the end of the free world as we know it.'&#8221;
O'Leary also noted that investors should not expect to perfectly time the bottom. &#8220;Never think you&#8217;re going to catch the bottom. I don't even guess to do that. I don't try and time the market.&#8221;
Trending: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
<h2 class="wp-block-heading">Stock Market Woes and Political Turmoil</h2>
O'Leary's comments come as markets struggle with fresh uncertainty, as the S&amp;P 500, the Dow Jones and the Nasdaq marked their <a href="https://www.benzinga.com/news/25/03/44308149/market-is-trying-to-rebound-keep-trump-off-x-says-jim-cramer-also-calls-out-canadas-carney-for-making-trump-">lowest levels since September</a>.
Market volatility has been fueled by President Donald Trump's latest tariff threats, which initially targeted Canadian metals and auto imports. While Trump later softened his stance on metal tariffs after Ontario Premier Doug Ford agreed to suspend an energy tax, uncertainty remains.
Trump has been clear about his strategy, according to O'Leary. &#8220;He wants to reset all the Tariff schedules from as far back as the Second World War and just have reciprocal tariffs,&#8221; he explained. &#8220;The thing about tariffs—you have to think of them as negotiating tools of economic warfare.&#8221;
See Also: This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a>
O'Leary cited examples such as dairy tariffs between the U.S. and Canada, where both sides have imposed steep duties. &#8220;After a while, both sides look at each other and say, ‘Well, we're both <a href="https://www.benzinga.com/news/25/03/44326649/does-canada-really-have-a-250-tariff-in-place-on-us-dairy-products-imported-into-canada-here-are-the-facts">tariffing each other at 243%</a>. There&#8217;s really no economic gain—<a href="https://www.benzinga.com/markets/cannabis/25/02/43476012/trumps-canada-tariffs-bffs-for-decades-what-went-wrong-can-it-really-be-about-fentanyl-unlikely">this is kind of stupid</a>.'&#8221;
O'Leary weighed in on the political situation in Canada as well, saying, &#8220;Unfortunately for Carney, he&#8217;s not going to be the one to negotiate. Unlikely he'll probably lose in the general election in the next 90 days to a man named Pierre Poilievre who's leading in the polls.&#8221;
<h2 class="wp-block-heading">Looking Ahead</h2>
O'Leary remains focused on <a href="https://www.benzinga.com/money/best-stocks-for-long-term-investment">long-term investing</a>, urging others not to panic. &#8220;Yes, there's volatility, nobody likes it, but the market was extremely expensive,&#8221; he said. &#8220;I have to admit, I did some buying lately. I'm seeing great companies that still have great growth prospects selling down.&#8221;
While some <a href="https://www.benzinga.com/media/25/03/44347282/recession-fears-gold-records-and-trade-wars-this-week-in-economics">fear a recession</a>, O'Leary does not see one in the immediate future. &#8220;I get the tear sheets for my own 54 private companies in all 11 sectors every Tuesday. I don't see [a recession] yet. Consumer&#8217;s still strong.&#8221;
Read Next:
<ul>
<li>Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

OUSA

O'Shares FTSE Russell Small Cap Quality Dividend ETF

OUSM

Kevin O'Leary Says 'Nobody Likes Volatility'—But Investors Must 'Hold Their Nose' And Buy 'When There's Blood In The Streets'

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 20 years by 2.16% on an annualized basis producing an average annual return of 10.36%. Currently, Travelers Companies has a market capitalization of $59.25 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 20 years ago, it would be worth $7,177.15 today based on a price of $261.32 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742424316_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Travelers Companies 20 Years Ago Would Be Worth Today

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 15 years by 8.51% on an annualized basis producing an average annual return of 19.63%. Currently, Progressive has a market capitalization of $160.20 billion. 
Buying $100 In PGR: If an investor had bought $100 of PGR stock 15 years ago, it would be worth $1,478.04 today based on a price of $273.29 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742423409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) has outperformed the market over the past 15 years by 3.66% on an annualized basis producing an average annual return of 14.78%. Currently, Intercontinental Exchange has a market capitalization of $99.97 billion. 
Buying $100 In ICE: If an investor had bought $100 of ICE stock 15 years ago, it would be worth $786.00 today based on a price of $174.00 for ICE at the time of writing.
<h3>Intercontinental Exchange's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742422513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Intercontinental Exchange 15 Years Ago Would Be Worth This Much Today

Earnings

WLDS

Wearable Devices 2024 EPS $(24.2) Vs. $(38.4) YoY, Revenues $522K Up From $82K YoY

Mortgage rates are rising again — and that&#8217;s bad news for homebuyers and refinancers. But, it may be an exciting opportunity to make money for investors looking at mortgage-backed securities (MBS) ETFs. 
With the most recent figures indicating a big <a href="https://www.benzinga.com/real-estate/reit/25/03/44396973/mortgage-applications-drop-as-rising-rates-squeeze-refinance-demand">decline in mortgage applications</a>, the conditions are ready for <a href="https://www.benzinga.com/etfs">MBS ETFs </a>to pick up steam as yields increase and prepayment risks get diminished.
<h1 class="wp-block-heading">Why MBS ETFs Stand To Gain</h1>
MBS ETFs are invested in mortgage-backed securities, which are home loan-backed debt securities. When housing rates rise, newly issued MBS gain more yield, which is desired by investors who want fixed-income exposure. 
At the same time, old MBS experience a deceleration in prepayments, as more homeowners choose not to refinance at higher rates.
There are some choice MBS ETFs that should profit through the prevailing conditions:
iShares MBS ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBB#NASDAQ">MBB</a>): One of the largest MBS ETFs, MBB primarily <a href="https://www.ishares.com/us/products/239465/ishares-mbs-etf">holds </a>agency-backed securities issued by Fannie Mae, Freddie Mac and Ginnie Mae.
Vanguard Mortgage-Backed Securities ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMBS#NASDAQ">VMBS</a>): This ETF <a href="https://investor.vanguard.com/investment-products/etfs/profile/vmbs#overview">offers </a>exposure to high-quality, government-backed MBS with relatively low volatility.
SPDR Bloomberg Barclays Mortgage Backed Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBG#NYSE">MBG</a>): MBG <a href="https://www.ssga.com/us/en/intermediary/etfs/spdr-portfolio-mortgage-backed-bond-etf-spmb">provides </a>a diversified portfolio of investment-grade MBS.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44385456/homebuilder-etfs-await-clearer-signals-amid-housing-market-uncertainty">Homebuilder ETFs Await Clearer Signals Amid Housing Market Uncertainty</a>
<h1 class="wp-block-heading">Shake-Up In The Mortgage Market And Rising Rates</h1>
The average 30-year fixed mortgage rate increased to 6.72% for the week through March 14, reversing a nine-week slide, the Mortgage Bankers Association (MBA) reported. The increase in this rate pushed refinancing applications down a substantial 13%, although purchase applications rose a mild 0.1%.
Investors are preparing for possible market movements after the Federal Open Market Committee&#8217;s decision on Wednesday<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44405112/tariff-inflation-may-be-transitory-powell-says-stocks-rally-bitcoin-clears-85000-as-bulls-return"> to hold rates at 4.25%-4.50%</a>. 
<h1 class="wp-block-heading">A Balancing Act</h1>
Though higher mortgage rates create headwinds for housing affordability and refinancing volume, they also offer fixed-income investors a chance. Higher yields and less prepayment risk potential make MBS ETFs an appealing option in this situation.
But it will be wise to stay guarded. The Fed&#8217;s policy orientation, inflation dynamics, and overall economic climate will be key in determining MBS performance. If rates keep on rising, MBS ETFs may face additional tailwinds. But if economic uncertainties force the Fed to shift gears in favor of rate cuts later this year, the picture will change once again.
For the time being, MBS ETFs are an attractive choice for investors seeking to take advantage of the changing interest rate landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44404071/betting-on-ubers-driverless-future-these-etfs-could-pay-off">Betting On Uber&#8217;s Driverless Future? These ETFs Could Pay Off</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Specialty ETFs

ETFs

Real Estate

VMBS

Higher Mortgage Rates Are Bad For Borrowers, But Great For These ETFs

He will maintain his position as Chairman of the Board of Directors, ensuring continuity and strategic oversight.

Management

TXO Partners Says Bob Simpson Will Retire From The Office Of CEO Of General Partner, Effective April 1, 2025; Gary Simpson And Brent Clum Both To Be Promoted To Serve As Co-CEOs

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 10 years by 6.51% on an annualized basis producing an average annual return of 17.02%. Currently, Live Nation Entertainment has a market capitalization of $28.86 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 10 years ago, it would be worth $482.30 today based on a price of $124.88 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742420712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Live Nation Entertainment 10 Years Ago Would Be Worth This Much Today

The transaction is expected to close by the end of the first quarter, subject to customary closing conditions.

Asset Sales

BRBS

Blue Ridge Bankshares Reveals Decision To Sell Mortgage Banking Division To An Unrelated Third-party Mortgage Company; No Terms Disclosed

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 15 years by 6.36% on an annualized basis producing an average annual return of 17.48%. Currently, RBC Bearings has a market capitalization of $10.64 billion. 
Buying $100 In RBC: If an investor had bought $100 of RBC stock 15 years ago, it would be worth $1,164.28 today based on a price of $338.34 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742419821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning RBC Bearings Stock In The Last 15 Years

As such, the Company will restate its financial statements for the Affected Periods in an amendment to the Q1 Form 10-Q, Q2 Form 10-Q and Q3 Form 10-Q, respectively, to be filed as soon as practicable.
The Company currently estimates that the impact of the accounting matter will result in changes in Q1 2024, Q2 2024 and Q3 2024 for Notes Payable, Interest Expense and Change in fair value of new convertible debentures, all on a non-cash basis.&nbsp;

KITT

Nauticus Robotics Says Certain Previously Issued Unaudited Condensed Consolidated Financial Statements Should Be Amended And Restated

Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year.

Earnings Beats

Lument Finance Trust Q4 2024 Adj EPS $0.10 Beats $0.09 Estimate

The reverse stock split will become effective at 4:30 p.m. Eastern Time on March 21, 2025, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on March 24, 2025.&nbsp;

Stock Split

ZCAR

Zoomcar Plans 1-For-20 Reverse Stock Split

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 11.0% on an annualized basis producing an average annual return of 29.46%. Currently, Primerica has a market capitalization of $9.66 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 5 years ago, it would be worth $4,288.53 today based on a price of $289.39 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742418914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Primerica 5 Years Ago Would Be Worth This Much Today

<h3>Gainers</h3>
<ul>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares rose 23.7% to $0.83 during Wednesday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Aureus Greenway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock moved upwards by 23.05% to $0.99. The market value of their outstanding shares is at $13.7 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares moved upwards by 12.63% to $0.2. The market value of their outstanding shares is at $10.3 million. </li>
<li>Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) shares moved upwards by 8.21% to $81.8. The company's market cap stands at $4.4 billion. The company's, Q4 earnings came out today. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares rose 5.95% to $0.25. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) stock moved upwards by 4.95% to $19.92. The market value of their outstanding shares is at $189.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 7.0% to $0.13 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) stock fell 5.02% to $0.41. The market value of their outstanding shares is at $8.2 million. </li>
<li>CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) stock fell 5.0% to $0.96. The company's market cap stands at $51.4 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares decreased by 4.83% to $0.38. The market value of their outstanding shares is at $6.1 million. </li>
<li>Newton Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) shares fell 4.47% to $2.14. </li>
<li>Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) stock decreased by 4.4% to $10.63. The market value of their outstanding shares is at $942.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

FIVE

LAKE

NWTG

PRTS

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

APDN

BCLI

DYAI

FGEN

IPSC

LENZ

SCNX

SHPH

VERO

Longevity Health Holdings, Inc. - Common Stock

XAGE

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) stock increased by 10.4% to $0.85 during Wednesday's after-market session. The market value of their outstanding shares is at $42.8 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) stock moved upwards by 9.19% to $0.66. The company's market cap stands at $19.2 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 8.25% to $2.73. The market value of their outstanding shares is at $91.1 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares rose 6.92% to $0.22. The market value of their outstanding shares is at $12.3 million. </li>
<li>Optex Systems Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPXS#NASDAQ">OPXS</a>) stock increased by 6.36% to $6.02. The company's market cap stands at $41.5 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares increased by 5.0% to $4.2. The market value of their outstanding shares is at $71.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares fell 13.2% to $0.23 during Wednesday's after-market session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock fell 8.59% to $1.81. The market value of their outstanding shares is at $26.9 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) shares fell 6.41% to $1.17. The market value of their outstanding shares is at $19.0 million. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) shares declined by 4.67% to $1.43. The company's market cap stands at $24.1 million. </li>
<li>Hyliion Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#AMEX">HYLN</a>) shares fell 4.22% to $1.59. The company's market cap stands at $277.9 million. </li>
<li>DLH Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) shares decreased by 3.8% to $4.56. The company's market cap stands at $65.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIK

CLIR

CNTM

DLHC

DXST

HYLN

MWYN

Nuveen Insured California Premium Fund Ii

NEOV

OPXS

PITA

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock moved upwards by 5.6% to $1.69 during Wednesday's after-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares rose 5.12% to $1.23. The company's market cap stands at $7.5 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares rose 5.01% to $3.56. The company's market cap stands at $37.5 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares increased by 4.97% to $0.2. The market value of their outstanding shares is at $13.9 million. </li>
<li>SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) shares moved upwards by 4.94% to $20.94. The company's market cap stands at $11.6 billion. </li>
<li>Backblaze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLZE#NASDAQ">BLZE</a>) stock increased by 4.89% to $5.79. The market value of their outstanding shares is at $314.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares fell 8.7% to $0.31 during Wednesday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 7.64% to $3.51. The company's market cap stands at $8.3 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares declined by 5.76% to $0.2. The market value of their outstanding shares is at $5.1 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares declined by 5.39% to $0.25. The market value of their outstanding shares is at $11.3 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock fell 4.67% to $1.43. The company's market cap stands at $52.4 million. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock decreased by 4.06% to $7.58. The market value of their outstanding shares is at $117.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AIXI

BLZE

CETX

CSAI

GRYP

OPTX

SAIL

SGMA

12 Information Technology Stocks Moving In Wednesday's After-Market Session

VCYT

Veracyte Plans To Present Multiple Abstracts At EAU25 Demonstrating Clinical Performance And Utility Of Its Decipher Tests In Prostate And Bladder Cancer

Press Releases

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders

Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner

General

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences

Health Care

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

Comments

Akoya Biosciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL